Ab&B Bio-Tech's (HKG:2627) new drug application for the quadrivalent subunit influenza vaccine for individuals aged six to 35 months was approved by China's National Medical Products Administration, a Wednesday Hong Kong bourse filing said.
Ab&B Bio-Tech's (HKG:2627) new drug application for the quadrivalent subunit influenza vaccine for individuals aged six to 35 months was approved by China's National Medical Products Administration, a Wednesday Hong Kong bourse filing said.
Comments